Effect of sevelamer on aortic pulse wave velocity in patients on hemodialysis: A prospective observational study

Hemodialysis International

Volumn 11, Issue SUPPL. 3, 2007, Pages

  Othmane, Taha El Hadj ^a   Bakonyi, Geza ^b   Egresits, Jozsef ^c   Fekete, Bertalan Cs ^a   Fodor, Erzsebet ^b   Jarai, Zoltan ^a   Jekkel, Csaba ^a   Nemcsik, Janos ^c   Szabo, Andras ^a   Szabo, Tamas ^b   Kiss, Istvan ^b,c   Tisler, Andras ^a,b  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b B Braun Avitum Hungary Zrt   (Hungary)

^c Szent Imre Hospital   (Hungary)

Author keywords

Arterial calcification; Arterial stiffness; Hemodialysis; Pulse wave velocity; Sevelamer

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM CARBONATE; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FETUIN; FETUIN A; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MATRIX GLA PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; REGULATOR PROTEIN; SEVELAMER; UNCLASSIFIED DRUG; VITAMIN D;

ADULT; AORTA DISEASE; ARTERY CALCIFICATION; BLOOD VESSEL CALCIFICATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG DOSE INCREASE; FEMALE; FOLLOW UP; HEART RATE; HEMODIALYSIS; HUMAN; LINEAR REGRESSION ANALYSIS; MALE; MULTIVARIATE ANALYSIS; OBSERVATIONAL STUDY; PULSE WAVE; STATISTICAL SIGNIFICANCE; TREATMENT DURATION;

BLOOD FLOW VELOCITY; CALCINOSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POLYAMINES; PROSPECTIVE STUDIES; PULSATILE FLOW; RENAL DIALYSIS; VASCULAR RESISTANCE;

EID: 34848899809     PISSN: 14927535     EISSN: 15424758     Source Type: Journal    
DOI: 10.1111/j.1542-4758.2007.00224.x     Document Type: Conference Paper

References (26)

1. Blacher J, Guerin AP, Pannier B, Marchais SJ, Safar ME, London GM. Impact of aortic stiffness on survival in end-stage renal disease. Circulation. 1999; 99: 2434-2439.
2. Shoji T, Emoto M, Shinohara K, et al. Diabetes mellitus, aortic stiffness, and cardiovascular mortality in end-stage renal disease. J Am Soc Nephrol. 2001; 12: 2117-2124.
3. Mitchell GF. Arterial stiffness and wave reflection in hypertension: Pathophysiologic and therapeutic implications. Curr Hypertens Rep. 2004; 6: 436-441.
4. O'Rourke MF. From theory to practice: Arterial hemodynamics in clinical hypertension. J Hypertens. 2002; 2010: 1901-1915.
5. London GM, Marchais SJ, Guerin AP, Metivier F. Arteriosclerosis, vascular calcifications and cardiovascular disease in uremia. Curr Opinion Nephrol Hypertens. 2005; 14: 525-531.
6. Guerin AP, Blacher J, Pannier B, Marchais SJ, Safar ME, London GM. Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure. Circulation. 2001; 103: 987-992.
7. Ketteler M, Gross ML, Ritz E. Calcification and cardiovascular problems in renal failure. Kidney Int. 2005; 67 (Suppl 94): 120-S127.
8. El-Abbadi M, Giachelli CM. Arteriosclerosis, calcium phosphate deposition and cardiovascular disease in uremia: Current concepts at the bench. Curr Opinion Nephrol Hypertens. 2005; 14: 519-524.
9. London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H. Arterial media calcification in end-stage renal disease: Impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant. 2003; 18: 1731-1740.
10. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002; 62: 245-252.
11. Block GA, Spiegel DM, Ehrlich J, et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int. 2005; 68: 1815-1824.
12. Ferramosca E, Burke S, Chasan-Taber S, Ratti C, Chertow GM, Raggi P. Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients. Am Heart J. 2005; 149: 820-825.
13. Salvi P, Lio G, Labat C, Ricci E, Pannier B, Benetos A. Validation of a new non-invasive portable tonometer for determining arterial pressure wave and pulse wave velocity: The pulsepen device. J Hypertens. 2004; 22: 2285-2293.
14. Mattu GS, Perry TL, Wright JM. Comparison of the oscillometric blood pressure monitor (BPM-100(Beta)) with the auscultatory mercury sphygmomanometer. Blood Pressure Monit. 2001; 6: 153-159.
15. Williams B, Lacy PS, Thom SM, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: Principal results of the conduit artery function evaluation (CAFE) study. Circulation. 2006; 113: 1213-1225.
16. Suki W, Zabaneh R, Cangiano J, et al. A prospective, randomized trial assessing the impact on outcomes of sevelamer in dialysis patients - the DCOR tial. Nephrol Dial Transplant. 2006; 21 (Suppl 4): 145 (Abstract).
17. Block G, Raggi P, Bellasi A, Ehrich J, Chonchol M, Spiegel D. Increased mortality associated with coronary calcium scores and calcium containing phosphate binders: Long term results from a randomized controlled trial in new dialysis patients. Nephrol Dial Transplant. 2006; 21 (Suppl 4): 294 (Abstract).
18. Takenaka T, Suzuki H. New strategy to attenuate pulse wave velocity in haemodialysis patients. Nephrol Dial Transplant. 2005; 20: 811-816.
19. Pannier B, Guerin AP, Marchais SJ, Safar M, London GM. Stiffness of capacitive and conduit arteries: Prognostic significance for end-stage renal disease patients. Hypertension. 2005; 45: 592-596.
20. London GM, Marchais SJ, Guerin AP, Metivier F, Adda H, Pannier B. Inflammation, arteriosclerosis, and cardiovascular therapy in hemodialysis patients. Kidney Int. 2003; 63 (Suppl 84): 88-93.
21. Ichihara A, Hayashi M, Kaneshiro Y, et al. Low doses of losartan and trandolapril improve arterial stiffness in hemodialysis patients. Am J Kidney Dis. 2005; 45: 866-874.
22. Ketteler M, Schlieper G, Floege J. Calcification and cardiovascular health: New insights into an old phenomenon. Hypertension. 2006; 47: 1027-1034.
23. Morena M, Terrier N, Jaussent I, et al. Plasma osteoprotegerin is associated with mortality in hemodialysis patients. J Am Soc Nephrol. 2006; 17: 262-270.
24. Stenvinkel P, Wang K, Qureshi AR, et al. Low fetuin-A levels are associated with cardiovascular death: Impact of variations in the gene encoding fetuin. Kidney Int. 2005; 67: 2383-2392.
25. Hermans MM, Brandenburg V, Ketteler M, et al. Study on the relationship of serum fetuin-A concentration with aortic stiffness in patients on dialysis. Nephrol Dial Transplant. 2006; 21: 1293-1299.
26. Schlieper G, Brandenburg V, Djuric Z, et al. Analysis of cardiovascular calcification, serum fetuin-A and osteoprotegerin in hemodialysis patients: The BASH study. Nephrol Dial Transplant. 2006; 21 (Suppl 4): 287 (Abstract).